Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Drugmaker will donate meds for US push to end HIV epidemic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2019 | 05:47pm EDT

WASHINGTONThe Health and Human Services Department says a major drugmaker has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year in support of the government's plan to end the epidemic in the U.S.

The pledge by California-based Gilead Sciences may last up to 11 years, said HHS Secretary Alex Azar. Gilead will donate its Truvada prevention pill until a second-generation version becomes available.

The Trump administration has set a goal of ending the HIV epidemic in the U.S. within 10 years.

Carl Schmid of the AIDS Institute called the donation "a really significant step," saying it will make the drug available to uninsured people. It lists for more than $20,000 per patient, per year.

HIV is the virus that causes AIDS.

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/16A Plan to Fight Hep C -- WSJ
DJ
09/12GILEAD SCIENCES : Ex-dividend day for
FA
09/09GILEAD SCIENCES : and the Elton John AIDS Foundation Launch RADIAN Initiative to..
BU
08/29GILEAD SCIENCES : An amendment to a SC 13D filing
PU
08/29AGENUS : Triggers 3rd Milestone in its Collaboration with Gilead
AQ
08/29GILEAD SCIENCES : Report
CO
08/27GILEAD SCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/26GILEAD SCIENCES : to Present at the Morgan Stanley Global Healthcare Conference ..
BU
08/26GILEAD SCIENCES : Alberta Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/26GILEAD SCIENCES : And galapagos complete closing of their transformative researc..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 272 M
Debt 2019 3 023 M
Yield 2019 3,81%
P/E ratio 2019 18,9x
P/E ratio 2020 11,6x
EV / Sales2019 3,89x
EV / Sales2020 3,75x
Capitalization 83 801 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,52  $
Last Close Price 66,17  $
Spread / Highest target 43,6%
Spread / Average Target 21,7%
Spread / Lowest Target -9,32%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.79%83 801
VERTEX PHARMACEUTICALS6.21%45 238
REGENERON PHARMACEUTICALS-22.86%31 527
GENMAB27.73%13 120
NEUROCRINE BIOSCIENCES, INC.42.01%9 287
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 518